Chargement...

Robocath demonstrates safety and efficacy of R-One

22 May 2018

100% technical success and no MACE[1] scored in first pre-clinical randomized trial

Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, announces today during the EuroPCR congress that its first robotic solution, R-OneTM, met all its primary efficacy and safety endpoints in the first pre-clinical study.

The prospective, randomized, controlled, multi-operator study evaluated the efficacity and safety of the robotic system compared to a manual procedure. Results showed that…

Learn more

Robocath sets up medical advisory board composed of International interventional cardiology Key Leaders

30 January 2018

Rouen, January 30, 2018 – Robocath, a company that conceives and develops cardiovascular robotic systems for the treatment of vascular diseases, announces today the creation of its medical advisory board including global experts and recognized leaders in interventional cardiology.

This committee will help define the clinical strategy of the company and more broadly contribute to the development of future generations of Robocath’s robotic system products.


Philippe Bencteux, president and founder of Robocath, said: “I’m particularly proud and pleased…

Learn more
30 January 2019

HIGH TECH CARDIO

21 May 2019

EuroPCR

#Robocath
Subscribe to our newsletter